Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06113237 · ClinicalTrials.gov registry record

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

A clinical trial of Pregnancy and Maternal Complications, sponsored by Jazz Pharmaceuticals.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT06113237: Recruiting study of Pregnancy and Maternal Complications, sponsored by Jazz Pharmaceuticals.

NCT06113237 is a study of Pregnancy and Maternal Complications that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 50 participants, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06113237, a study of Pregnancy and Maternal Complications, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.

Primary Outcome

Rate of Major congenital malformation (MCM) identified in the developing neonate and infant through 12 months of age

Interventions

  • DRUG Epidiolex

Study Locations (1)

West Virginia

  • United Biosource LLC - Morgantown

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-08-05
Est. Completion 2033-08-31
Jazz Pharmaceuticals

128 total trials

What NCT06113237 shows while recruiting

NCT06113237 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (94% lower).

The record links to 4 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which Epidiolex is the first listed.

NCT06113237 reports a single indexed study location in West Virginia.

Frequently Asked Questions

What is clinical trial NCT06113237 about?

NCT06113237 is a clinical study titled "Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy". The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.

What is the current status of trial NCT06113237?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-08-05. Estimated completion is 2033-08-31.

What conditions does trial NCT06113237 study?

This clinical trial studies the following conditions: Pregnancy, Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse.

What interventions are being tested in trial NCT06113237?

The interventions under investigation include: Epidiolex (DRUG).

Who is sponsoring clinical trial NCT06113237?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06113237 being conducted?

This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pregnancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06113237's enrollment target sits among peer trials

50 152nd of 191 higher than 34 of 191 other Pregnancy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pregnancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06113237, the US trial registry maintained by the National Library of Medicine. NCT06113237 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.